Gabapentin 1800mg/day Safe, Effective for PHN, Says Study

the MPR take:

In a recent study published in the Journal of Clinical Pharmacy and Therapeutics, the use of 1800mg/day of gabapentin was found to significantly reduce pain associated with post-herpetic neuralgia (PHN) up to 14 weeks; treatment also appeared to be safe up to 24 weeks.  The study compared gabapentin 1800mg/day to placebo with primary outcomes being reduction in 24-hour average pain intensity scores, pain intensity reductions of 50% and 30%, and associated adverse effects of therapy. Six randomized controlled trials were included in the analysis which showed that 1800mg/day of gabapentin reduced 24-hour average pain intensity scores and yielded an improvement in pain intensity. While somnolence, dizziness, and peripheral edema did occur, adverse effects of therapy were generally mild to moderate.

Gabapentin has been used for the management of post-herpetic neuralgia (PHN). However, inconsistent results have been reported. This meta-analysis was performed to assess the efficacy and safety of gabapentin 1800 mg/day in PHN patients by conducting a meta-analysis.